Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront Temozolomide for Unresectable Low Grade Glioma
NCT02209428Phase 2Unknown
- Sponsor
- Huashan Hospital
- Start
- Jun 2014
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in low-grade glioma (LGG) (2 arms), sponsored by Huashan Hospital. Primary endpoints: Objective Response Rate up to 2 years and Velocity of Diameter Evolution up to 2 years. Status: unknown.
02
Drugs
temozolomide
03
Conditions
low-grade glioma (LGG)
Beyond the preview
Go deeper on NCT02209428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209428.